ASX:BB1 ASX:BB1 ASX Announcement 20 November 2026 BlinkLab Presents Digital Biomarker Data in Autism and ADHD at Neuroscience 2026, the World’s Largest Neuroscience Conference Highlights ? Two data presentations at Neuroscience 2026: BlinkLab and its academic collaborators presented their autism...
BB1 Presents at the World's Largest Neuroscience Conference
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The presentations highlighted objective measures that could aid in diagnosing autism and monitoring ADHD symptoms. The company aims to enhance clinical adoption of its products through increased visibility at this major neuroscience conference. BlinkLab's regulatory program for its diagnostic tool remains a priority, with an FDA submission expected soon.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from BlinkLab
- BlinkLab Receives $1.22 Million R&D Tax Incentive Refund
- Positive Results in Genetic Autism Study Ahead of Schedule
- Trading Halt
- Quarterly Activities/Appendix 4C Cash Flow Report
- Commencement of Nationwide Autism Screening in Morocco
Follow BlinkLab into a list and get an email when it puts out news.
Follow BlinkLab